Product Information
FT CHEST CONG RLF PE 400-10 MG is a generic product labeled by Strategic Sourcing Services LLC, priced at $0.0915 per EA under NDC 70677105601. Its NADAC has been published 161 times since Sep 6, 2023.
Strength
400; 10 mg/1; mg/1
Manufacturer
Strategic Sourcing Services LLCNDC
70677105601
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
1/27/2023
Pharmacological Classes
Price Statistics
The NADAC for FT CHEST CONG RLF PE 400-10 MG has been published 161 times since Sep 6, 2023, and over the history we have for it it has risen 12.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0915 per EA |
|---|---|
| All-time high | $0.0915 (Sep 30, 2026) |
| All-time low | $0.0740 (Feb 18, 2026) |
| 52-week high | $0.0915 |
| 52-week low | $0.0740 |
| Median price | $0.0829 |
| Average price | $0.0829 |
| Largest weekly change | +10.0% (Dec 20, 2023) |
| Weeks tracked | 161 |
| Tracking since | Sep 6, 2023 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 24% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strategic Sourcing Services LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Guaifenesin/phenylephrine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Expectorant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FT CHEST CONG RLF PE 400-10 MG?
The current National Average Drug Acquisition Cost (NADAC) for FT CHEST CONG RLF PE 400-10 MG, manufactured by Strategic Sourcing Services LLC, is $0.0915 per EA (NDC 70677105601), effective Sep 30, 2026.
How has the price of FT CHEST CONG RLF PE 400-10 MG changed over time?
Over the history we have for it, the NADAC for FT CHEST CONG RLF PE 400-10 MG has risen 12.5%. It has been tracked across 161 weekly CMS publications since Sep 6, 2023.
What are the highest and lowest recorded NADAC prices for FT CHEST CONG RLF PE 400-10 MG?
Since Sep 6, 2023, the NADAC for FT CHEST CONG RLF PE 400-10 MG has ranged from a low of $0.0740 (Feb 18, 2026) to a high of $0.0915 (Sep 30, 2026), with a median of $0.0829 per EA.
Are there cheaper alternatives to FT CHEST CONG RLF PE 400-10 MG?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SM CHEST CONG RELIEF PE CAPLET, is $0.0697 per EA — about 24% below FT CHEST CONG RLF PE 400-10 MG.
Who manufactures FT CHEST CONG RLF PE 400-10 MG?
FT CHEST CONG RLF PE 400-10 MG (NDC 70677105601) is labeled by Strategic Sourcing Services LLC, and CMS classifies it as a generic product.